Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 11,463,072	$ 13,436,714
Tax receivable	322,381	255,705
Prepaid expenses and other current assets	1,247,828	1,205,398
Total current assets	13,033,281	14,897,817
Other assets	175,131	6,724
Equipment, net	3,055	3,560
Total assets	13,211,467	14,908,101
Current liabilities:
Accounts payable and accrued expenses	1,472,926	1,273,296
Total current liabilities	1,472,926	1,273,296
Funds held for subsidiary private offering		475,000
Total liabilities	1,472,926	1,748,296
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.0001 par value; 200,000,000 shares authorized; 14,021,185 shares issued and 13,948,822 shares outstanding at March 31, 2023 and 13,964,485 shares issued and 13,892,122 shares outstanding at December 31, 2022	1,403	1,397
Additional paid-in capital	52,251,823	51,156,597
Accumulated other comprehensive income	82,547	87,021
Accumulated deficit	(40,464,911)	(37,985,247)
Treasury stock at cost, 72,363 shares as of March 31, 2023 and December 31, 2022	(99,963)	(99,963)
Total Immix Biopharma, Inc. stockholders’ equity	11,770,899	13,159,805
Non-controlling interests	(32,358)
Total stockholders’ equity	11,738,541	13,159,805
Total liabilities and stockholders’ equity	$ 13,211,467	$ 14,908,101